• Super-Enhancer-Driven LINC01977 and TGF-β/SMAD3 in Early LUA

  2026-08-06

  Zhang et al. reveal that super-enhancer hijacking of LINC01977 drives malignancy in early-stage lung adenocarcinoma by activating the canonical TGF-β/SMAD3 pathway. This mechanistic insight highlights LINC01977 as a potential therapeutic target and underscores the value of ALK5 pathway inhibition in understanding lung cancer progression.

• ERK5/MAPK Pathway in Vitamin D3-Induced AML Differentiation

  2026-08-06

  This study elucidates the distinct and essential roles of the ERK5/MAPK pathway in the terminal differentiation of myeloid leukemia cells induced by 1α,25-dihydroxyvitamin D3. The findings demonstrate that ERK5 inhibition selectively impacts differentiation marker expression and cell cycle progression, offering new insights for combination therapies in cancer research.

• Strategic GSK-3 Inhibition: Unlocking Wnt Pathways in Transl

  2026-08-05

  This thought-leadership article explores the mechanistic role of CHIR-99021 (CT99021) in modulating the Wnt/β-catenin signaling pathway, with a focus on strategic guidance for translational researchers. Integrating key findings from recent literature, the article highlights how precise GSK-3 inhibition enables advances in pluripotency maintenance, cardiomyogenic differentiation, and protocol optimization. It further distinguishes itself by critically assessing the interplay between pathway antagonists such as SOX9 and the promise of small-molecule tools like CHIR-99021, providing actionable recommendations for robust experimental design and future-facing research.

• Novobiocin: Aminocoumarin Antibiotic Workflows & Innovations

  2026-08-05

  Novobiocin, a dual-action aminocoumarin antibiotic, enables precise inhibition of bacterial DNA replication and membrane synthesis, unlocking advanced antibacterial, antiparasitic, and antiviral research applications. This article delivers actionable workflows, troubleshooting insights, and protocol optimizations rooted in contemporary evidence—including a novel protoplast assay innovation.

• Anp32e Drives Renal Fibrosis via TGF-β1/Smad3 Pathway Activa

  2026-08-04

  This study demonstrates that Anp32e promotes renal interstitial fibrosis by upregulating fibrosis-related proteins through activation of the TGF-β1/Smad3 signaling pathway. Crucially, pharmacological inhibition of ALK5 with SB 431542 reverses these pro-fibrotic effects in vitro, providing mechanistic insight and suggesting new targets for therapeutic intervention in chronic kidney disease.

• CBD Attenuates Orofacial Pain and Affective Deficits via Mul

  2026-08-04

  This study demonstrates that cannabidiol (CBD) suppresses both sensory and affective components of orofacial inflammatory pain in mice. Mechanistic insights reveal coordinated modulation of peripheral and central cannabinoid and serotonergic pathways, supporting CBD’s translational potential for multidimensional pain management.

• Inflammatory Mechanisms and Biomarker Strategies in Ischemic

  2026-08-03

  This review systematically synthesizes current knowledge on the inflammatory response in ischemic stroke, emphasizing the dual role of neuroinflammation in both injury progression and repair. It highlights advances in biomarker-based diagnosis and treatment, presenting a unified framework for translational research and clinical application.

• YC-1: sGC Activator & HIF-1α Inhibitor for Tumor Research

  2026-08-03

  YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol is a highly pure small molecule sGC activator and HIF-1α inhibitor. It is widely used to investigate tumor angiogenesis, hypoxia signaling, and apoptosis in cancer research. APExBIO supplies YC-1 with verified purity and solubility, supporting advanced experimental workflows.

• Cholesterol (SKU B1702): Optimizing Membrane Assays in the L

  2026-08-02

  This article addresses common challenges in cell viability and membrane fluidity assays by exploring the scientific and practical merits of Cholesterol (SKU B1702) from APExBIO. Scenario-driven Q&A blocks guide researchers on reproducibility, solubility, and vendor reliability, supporting data-backed decision making for advanced lipid metabolism research.

• SCH772984: Next-Gen ERK1/2 Inhibitor for Tumor Pathway Disse

  2026-08-01

  Explore how SCH772984, a selective ERK1/2 inhibitor, enables precise dissection of MAPK/ERK pathway signaling in complex tumor models. This article goes beyond protocols to analyze emerging mechanistic insights and practical assay implications, offering a new perspective for advanced oncology research.

• ERK5 and ERK1/2 Roles in Vitamin D-Induced AML Differentiati

  2026-07-31

  This study reveals the distinct and critical involvement of the ERK5/MAPK pathway in the terminal differentiation of myeloid leukemia cells driven by 1α,25-(OH)2 vitamin D3. By dissecting the effects of selective pathway inhibition, the research clarifies cell cycle regulation and suggests new combinatorial strategies for acute myeloid leukemia therapy.

• Isorhamnetin: Advancing Oocyte Maturation via PI3K/Akt Pathw

  2026-07-31

  Isorhamnetin, a potent flavonoid modulator, elevates in vitro oocyte maturation by regulating PI3K/Akt and MAPK signaling, providing a robust edge in oxidative stress and apoptosis research. This guide translates bench breakthroughs into actionable protocol upgrades and troubleshooting strategies for reproductive and cellular stress assays.

• AI-10-49 and the N-MYC/eIF4G1 Axis: Innovating AML Research

  2026-07-30

  This article explores the mechanistic and translational impact of AI-10-49, a selective CBFβ-SMMHC inhibitor, on acute myeloid leukemia—spotlighting the pivotal N-MYC/eIF4G1 axis in inv(16) AML. It provides strategic guidance for researchers, integrates leading evidence, and frames AI-10-49 as a next-generation research tool for unlocking new therapeutic avenues.

• Jasplakinolide in Chemical Genetics: Redefining Actin Assays

  2026-07-30

  Explore how Jasplakinolide, a premier actin polymerization inducer, enables advanced chemical genetics and cytoskeletal dynamics studies. This article uniquely bridges actin research with actionable assay design, grounded in leading-edge scientific evidence.

• AZD1390: Ultra-Potent ATM Kinase Inhibitor for DNA Repair St

  2026-07-29

  AZD1390 is a highly selective ATM kinase inhibitor that enables precise interrogation of DNA double-strand break repair and cell cycle regulation in cancer research. It delivers sub-nanomolar potency, especially in radiosensitizing glioma and lung cancer cells. Validated in cellular and in vivo models, AZD1390 advances mechanistic studies and translational workflows.

16856 records 1/1124 page Next 12345 下5页 Last page